NO20060019L - Fremgangsmater og preparater for interferonterapi - Google Patents
Fremgangsmater og preparater for interferonterapiInfo
- Publication number
- NO20060019L NO20060019L NO20060019A NO20060019A NO20060019L NO 20060019 L NO20060019 L NO 20060019L NO 20060019 A NO20060019 A NO 20060019A NO 20060019 A NO20060019 A NO 20060019A NO 20060019 L NO20060019 L NO 20060019L
- Authority
- NO
- Norway
- Prior art keywords
- interferon
- protein
- delivery
- syn3
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47592603P | 2003-06-04 | 2003-06-04 | |
US10/455,215 US20040014709A1 (en) | 1996-01-08 | 2003-06-04 | Methods and compositions for interferon therapy |
PCT/US2004/017788 WO2004108088A2 (fr) | 2003-06-04 | 2004-06-04 | Procedes et compositions pour la therapie a l'interferon |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060019L true NO20060019L (no) | 2006-03-03 |
Family
ID=33513856
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060019A NO20060019L (no) | 2003-06-04 | 2006-01-03 | Fremgangsmater og preparater for interferonterapi |
Country Status (9)
Country | Link |
---|---|
US (1) | US20050025742A1 (fr) |
EP (2) | EP1629085A2 (fr) |
JP (3) | JP2007526219A (fr) |
KR (1) | KR20060012661A (fr) |
AU (2) | AU2004245995A1 (fr) |
BR (1) | BRPI0410915A (fr) |
CA (2) | CA2528136A1 (fr) |
NO (1) | NO20060019L (fr) |
WO (1) | WO2004108088A2 (fr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US20040014709A1 (en) * | 1996-01-08 | 2004-01-22 | Canji, Inc. | Methods and compositions for interferon therapy |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US7002027B1 (en) | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
CA2470999C (fr) * | 2001-12-20 | 2017-02-21 | Schering-Plough Corporation | Compositions de syn3 et procedes associes |
AU2003224650A1 (en) * | 2002-03-02 | 2003-09-16 | University Of South Florida | A method for treating allergic disease and asthma by recombinant adenovirus-and adeno-associated virus-mediated ifn-gamma gene |
AU2003225281A1 (en) * | 2002-04-30 | 2003-11-17 | University Of South Florida | Materials and methods for prevention and treatment of rna viral diseases |
US7595303B1 (en) | 2002-09-05 | 2009-09-29 | University Of South Florida | Genetic adjuvants for immunotherapy |
US20070116767A1 (en) * | 2003-02-14 | 2007-05-24 | Mohapatra Shyam S | Chitosan-microparticles for ifn gene delivery |
NZ543970A (en) * | 2003-06-04 | 2008-09-26 | Canji Inc | Methods and compositions for interferon therapy |
SG133594A1 (en) * | 2003-12-10 | 2007-07-30 | Canji Inc | Methods and compositions for treatment of interferon-resistant tumors |
US20050266093A1 (en) * | 2004-04-27 | 2005-12-01 | Mohapatra Shyam S | Nanogene therapy for cell proliferation disorders |
TWI305230B (en) * | 2004-06-25 | 2009-01-11 | Univ Feng Chia | Nucleic acid construct and expression vector for enhancing the production of recombinant protein, and method for the massive production of recombinant protein |
WO2006065827A2 (fr) | 2004-12-13 | 2006-06-22 | Canji, Inc. | Lignees cellulaires pour la production d'adenovirus defectifs pour la replication |
US20070249043A1 (en) | 2005-12-12 | 2007-10-25 | Mayall Timothy P | Adenoviral expression vectors |
CN105209054A (zh) | 2013-04-18 | 2015-12-30 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
CN108025040A (zh) | 2015-08-25 | 2018-05-11 | 阿尔莫生物科技股份有限公司 | 使用白介素-10治疗疾病和病症的方法 |
US11311487B2 (en) | 2016-04-14 | 2022-04-26 | Trizell Ltd. | Viral vector stabilization |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4456748A (en) * | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4678751A (en) * | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US6936694B1 (en) * | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US5554386A (en) * | 1986-07-03 | 1996-09-10 | Advanced Magnetics, Inc. | Delivery of therapeutic agents to receptors using polysaccharides |
US5166320A (en) * | 1987-04-22 | 1992-11-24 | University Of Connecticut | Carrier system and method for the introduction of genes into mammalian cells |
US5013566A (en) * | 1988-12-19 | 1991-05-07 | Sampson Michael James | Process for obtaining improved yields from plants used for hay making by using a coating agent |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5108921A (en) * | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
US5298222A (en) * | 1989-08-09 | 1994-03-29 | Osteotech, Inc. | Process for disinfecting musculoskeletal tissue and tissues prepared thereby |
US5013556A (en) * | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5118512A (en) * | 1990-01-23 | 1992-06-02 | Osteotech, Inc. (A Delaware Corp.) | Process for cryopreserving biological materials and materials prepared thereby |
US5279833A (en) * | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
US5795870A (en) * | 1991-12-13 | 1998-08-18 | Trustees Of Princeton University | Compositions and methods for cell transformation |
US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
US5346701A (en) * | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5496731A (en) * | 1993-03-25 | 1996-03-05 | Xu; Hong-Ji | Broad-spectrum tumor suppressor genes, gene products and methods for tumor suppressor gene therapy |
WO1995002698A1 (fr) * | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Compositions et procedes servant a transfecter des cellules eucaryotes |
US5804566A (en) * | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
US6210939B1 (en) * | 1993-10-25 | 2001-04-03 | Canji, Inc. | Recombinant adenoviral vector and methods of use |
US5837533A (en) * | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5552309A (en) * | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
US6392069B2 (en) * | 1996-01-08 | 2002-05-21 | Canji, Inc. | Compositions for enhancing delivery of nucleic acids to cells |
US7002027B1 (en) * | 1996-01-08 | 2006-02-21 | Canji, Inc. | Compositions and methods for therapeutic use |
US5789244A (en) * | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
US5831062A (en) * | 1996-05-09 | 1998-11-03 | Amgen Inc. | Use of the human interferon consensus gene for gene therapy |
-
2004
- 2004-06-04 BR BRPI0410915-5A patent/BRPI0410915A/pt not_active IP Right Cessation
- 2004-06-04 AU AU2004245995A patent/AU2004245995A1/en not_active Abandoned
- 2004-06-04 JP JP2006515161A patent/JP2007526219A/ja active Pending
- 2004-06-04 JP JP2006515206A patent/JP2006526661A/ja not_active Withdrawn
- 2004-06-04 EP EP04754260A patent/EP1629085A2/fr not_active Withdrawn
- 2004-06-04 CA CA002528136A patent/CA2528136A1/fr not_active Abandoned
- 2004-06-04 WO PCT/US2004/017788 patent/WO2004108088A2/fr active Application Filing
- 2004-06-04 KR KR1020057023355A patent/KR20060012661A/ko not_active Application Discontinuation
- 2004-06-04 US US10/861,654 patent/US20050025742A1/en not_active Abandoned
- 2004-06-04 EP EP04754399A patent/EP1628624A2/fr not_active Withdrawn
- 2004-06-04 AU AU2004245074A patent/AU2004245074A1/en not_active Abandoned
- 2004-06-04 CA CA002527658A patent/CA2527658A1/fr not_active Abandoned
-
2006
- 2006-01-03 NO NO20060019A patent/NO20060019L/no not_active Application Discontinuation
-
2007
- 2007-06-01 JP JP2007147517A patent/JP2007269808A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2006526661A (ja) | 2006-11-24 |
EP1629085A2 (fr) | 2006-03-01 |
EP1628624A2 (fr) | 2006-03-01 |
US20050025742A1 (en) | 2005-02-03 |
KR20060012661A (ko) | 2006-02-08 |
WO2004108088A3 (fr) | 2006-04-20 |
JP2007269808A (ja) | 2007-10-18 |
WO2004108088A2 (fr) | 2004-12-16 |
BRPI0410915A (pt) | 2006-06-27 |
AU2004245074A1 (en) | 2004-12-16 |
CA2528136A1 (fr) | 2004-12-16 |
JP2007526219A (ja) | 2007-09-13 |
AU2004245995A1 (en) | 2004-12-16 |
CA2527658A1 (fr) | 2004-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20060019L (no) | Fremgangsmater og preparater for interferonterapi | |
AU2017312113B2 (en) | Nucleic acid products and methods of administration thereof | |
Prodinger et al. | Epidermolysis bullosa: Advances in research and treatment | |
Pezzulo et al. | HSP90 inhibitor geldanamycin reverts IL-13–and IL-17–induced airway goblet cell metaplasia | |
Scharffetter et al. | Synergistic effect of tumor necrosis factor-α and interferon-γ on collagen synthesis of human skin fibroblasts in vitro | |
Tian et al. | Myocardin-related transcription factor A (MRTF-A) plays an essential role in hepatic stellate cell activation by epigenetically modulating TGF-β signaling | |
Sugahara et al. | Alveolar epithelial cells: differentiation and lung injury | |
Yang et al. | Fibroblast activation protein activates macrophages and promotes parenchymal liver inflammation and fibrosis | |
CN109477102A (zh) | 核酸产品及其施用方法 | |
Hong et al. | Stem cell aging in the skeletal muscle: The importance of communication | |
Li et al. | Cryptotanshinone downregulates the profibrotic activities of hypertrophic scar fibroblasts and accelerates wound healing: A potential therapy for the reduction of skin scarring | |
WO2008098569A3 (fr) | Molécules biologiquement actives, notamment à base de pna et de sirna, procédé permettant leur activation à spécificité cellulaire, et kit d'application pour leur administration | |
CO5700786A2 (es) | Metodos y composiciones para terapia con interferon | |
Zhang et al. | Erythropoietin derived peptide improved endoplasmic reticulum stress and ischemia-reperfusion related cellular and renal injury | |
Song et al. | Irisin reverses platelet derived growth factor-BB-induced vascular smooth muscle cells phenotype modulation through STAT3 signaling pathway | |
JP6073238B2 (ja) | 皮膚細胞分化促進物質のスクリーニング方法 | |
Kook et al. | COMP-angiopoietin 1 increases proliferation, differentiation, and migration of stem-like cells through Tie-2-mediated activation of p38 MAPK and PI3K/Akt signal transduction pathways | |
MX2021011037A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos de fenilalanina hidroxilasa (pah). | |
Guo et al. | Potential role of MG53 in the regulation of transforming-growth-factor-β1-induced atrial fibrosis and vulnerability to atrial fibrillation | |
Shrestha et al. | Proteome analysis of secretions from human monocyte-derived macrophages post-exposure to biomaterials and the effect of secretions on cardiac fibroblast fibrotic character | |
Locatelli et al. | Targeting the cardiomyocyte cell cycle for heart regeneration | |
Drzeniek et al. | Immuno-engineered mRNA combined with cell adhesive niche for synergistic modulation of the MSC secretome | |
MX2022011805A (es) | Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con factor ix. | |
Endo | Postnatal skeletal muscle myogenesis governed by signal transduction networks: MAPKs and PI3K–Akt control multiple steps | |
De Berdt et al. | The human dental apical papilla promotes spinal cord repair through a paracrine mechanism |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |